← All trials
NCT06307652
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 12, 2024
- Primary completion
- Jun 11, 2027
- Completion date
- Jun 11, 2027
- First posted
- Mar 13, 2024
- Last posted
- Oct 22, 2024
- Enrollment
- 4800
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AstraZenecaLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.